药用植物临床前安全性和毒性综述
作者:
作者单位:

Division of Toxicology and Experimental Medicine, CSIR-Central Drug Research Institute (CSIR-CDRI), Lucknow 226031, India

作者简介:

通讯作者:

中图分类号:

基金项目:


A Comprehensive Review on Preclinical Safety and Toxicity of Medicinal Plants
Author:
Affiliation:

Division of Toxicology and Experimental Medicine, CSIR-Central Drug Research Institute (CSIR-CDRI), Lucknow 226031, India

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    背景:全球有 80% 的人使用植物衍生产品来治疗或预防疾病。对药用植物的普遍看法是,它们安全且无不良影响,然而,约有 1,500,000 种植物含有有毒物质。目的:该综述旨在综述采用临床前模型,并通过口服途径给药的药用植物提取物/萃取物的毒性。方法:从 PubMed 和 Google Scholar 等数据库中搜索相关研究详情。对所选研究进行了参考文献人工筛选,以确定相关论文,搜索时未设置语言限制。结果:收录的研究均以啮齿动物为对象,测试物均为口服给药。检索结果显示,Datura stramonium L., Chrysophyllum pruniforme Engl, Quassia amara L等33 种广泛使用的植物或其制品具有显著毒性,我们对这些植物中的植物化学物质进行了总结。通过系统性回顾,我们发现了大量报道安全性和毒性问题的药用植物提取物。结论:今后,需要对草药进行临床前毒代动力学研究,并确定其无可见有害作用水平(No-observed adverse effect level,NOAEL),以进行全面的安全性评估。最后,还应研究草药与常用/非处方药在代谢方面的相互作用。

    Abstract:

    Background Globally, 80% people use plant-derived products for treating or preventing diseases. One prevalent perception about medicinal plants is that they are safe and devoid of adverse effects. However, approximately 1,50,000 plants contain toxic substances. Objective The present review focuses on medicinal plant extracts/fractions toxicity assessments made in preclinical models by oral route. Methods Detail studies were searched from databases including PubMed and Google Scholar. A manual reference screening of the selected studies was done to identify relevant articles, with no language restriction being imposed at the time of searching. Results The studies included were performed in rodents, and the test substances were administered orally. Our search revealed 33 widely used plants or products with significant toxicity, and phytochemicals from these plants have been summarized. Through a systematic review, we identified a plethora of medicinal plant extracts reporting safety and toxicity concerns. Conclusion In the future, preclinical toxicokinetic studies of herbs and the determination of their no-observed-adverse-effect levels are required for a complete safety assessment. Finally, the interaction of herbs with commonly used/over-the-counter drugs in terms of the latter's metabolic profile should be undertaken.

    参考文献
    相似文献
    引证文献
引用本文
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2024-04-15
  • 出版日期: